US Bancorp DE Acquires 1,601 Shares of Insmed Incorporated (NASDAQ:INSM)

US Bancorp DE raised its position in shares of Insmed Incorporated (NASDAQ:INSM) by 20.2% during the 4th quarter, HoldingsChannel.com reports. The fund owned 9,533 shares of the biopharmaceutical company’s stock after acquiring an additional 1,601 shares during the period. US Bancorp DE’s holdings in Insmed were worth $658,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. V Square Quantitative Management LLC boosted its position in Insmed by 60.3% during the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 248 shares in the last quarter. Spire Wealth Management bought a new stake in shares of Insmed in the 4th quarter worth approximately $47,000. Venturi Wealth Management LLC bought a new stake in shares of Insmed in the 4th quarter worth approximately $86,000. Quantbot Technologies LP bought a new stake in shares of Insmed in the 3rd quarter worth approximately $133,000. Finally, Avior Wealth Management LLC bought a new stake in shares of Insmed in the 4th quarter worth approximately $157,000.

Insmed Price Performance

Shares of INSM opened at $73.70 on Wednesday. The firm has a market cap of $13.34 billion, a PE ratio of -13.18 and a beta of 1.28. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The firm has a fifty day simple moving average of $75.83 and a two-hundred day simple moving average of $73.71. Insmed Incorporated has a 1-year low of $21.92 and a 1-year high of $84.91.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). The company had revenue of $104.44 million for the quarter, compared to analysts’ expectations of $102.31 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. On average, equities analysts anticipate that Insmed Incorporated will post -4.56 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently commented on INSM. JPMorgan Chase & Co. boosted their price target on Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a research report on Friday, February 7th. HC Wainwright reissued a “buy” rating and issued a $90.00 price target on shares of Insmed in a research report on Friday, February 21st. Morgan Stanley boosted their price target on Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, February 6th. Cantor Fitzgerald restated an “overweight” rating on shares of Insmed in a report on Wednesday, February 19th. Finally, UBS Group boosted their price objective on shares of Insmed from $105.00 to $110.00 and gave the stock a “buy” rating in a report on Thursday, March 6th. One analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $93.33.

Insider Buying and Selling at Insmed

In other news, insider Martina M.D. Flammer sold 6,172 shares of the company’s stock in a transaction on Friday, January 10th. The stock was sold at an average price of $63.64, for a total value of $392,786.08. Following the completion of the sale, the insider now directly owns 101,549 shares in the company, valued at $6,462,578.36. This represents a 5.73 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO William Lewis sold 18,750 shares of the company’s stock in a transaction on Thursday, December 19th. The stock was sold at an average price of $69.91, for a total value of $1,310,812.50. Following the completion of the sale, the chief executive officer now owns 384,960 shares of the company’s stock, valued at $26,912,553.60. This trade represents a 4.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 550,957 shares of company stock worth $42,859,028. Insiders own 4.60% of the company’s stock.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.